Navigation Links
A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence
Date:5/7/2008

PARSIPPANY, N.J., May 7 /PRNewswire/ -- GlaxoSmithKline (GSK) Consumer Healthcare, marketer of the leading smoking cessation products including Nicorette(R) gum, NicoDerm(R) CQ(R) patch, and Commit(R) lozenge, applauds the release of the updated 2008 U.S. Public Health Service (PHS) Guideline on Treating Tobacco Use and Dependence. Too many smokers lower their chances of quitting by relying on cold turkey approaches to become tobacco-free. The Guideline is an important validation of the need for clinicians to recommend the use of effective tobacco dependence counseling and medication. The Guideline reflects considerable progress in tobacco cessation research over the past decade to help identify the most effective strategies at reducing tobacco dependence.

We believe the 2008 update is of particular significance as it includes the addition of the Commit nicotine lozenge which can reliably increase long-term smoking abstinence. The Commit lozenge is approved by the U.S. Food and Drug Administration (FDA) to help withdrawal symptoms and cravings associated with quitting smoking, has a groundbreaking dosage selector (Time to First Cigarette) so a smoker can choose the strength that's right for them and provides low, safe doses of nicotine to ease withdrawal from cigarettes.

The updated Guideline reflects the distillation of thousands of research articles, and continues to recommend nicotine replacement products (NRT), such as Nicorette gum and NicoDerm CQ patch, as a first-line therapy for quitting, as they "increase significantly rates of long-term smoking abstinence."(1)

GlaxoSmithKline's NRT brands offer a step-down therapy to help smokers break their dependence on tobacco and safely wean off nicotine. Clinical trials have demonstrated that these brands double a smoker's chances of quitting versus placebo.(2) They are extensively proven to significantly reduce cravings and other withdrawal symptoms during quitting, allowing smokers to focus on behavior change. More than 110 clinical trials involving more than 40,000 participants and extensive consumer use over more than 20 years have proven the safety and efficacy of NRT when used as directed.(3)

Since becoming available without a prescription in 1996, GSK's NRT smoking cessation brands have helped millions of people around the world quit smoking and, as a result, have significantly reduced their exposure to the risks of cancer and other smoking-related diseases.(4)

GSK Consumer Healthcare offers smokers a variety of customized quit-smoking resources, including tools and information at http://www.Way2Quit.com, free proven tailored quit plans through http://www.CommittedQuitters.com and free access to GSK-certified stop-smoking counselors weekdays at 1-877-NO-ASHES where a smoker can develop an individualized support plan and receive customized tips from experts.

Quitting smoking is the most important step smokers can take to improve their health -- and it's also one of the most difficult. By developing innovative new products and support systems to improve the quit experience, GSK Consumer Healthcare is working to inspire and enable every smoker to quit.

(1) 2008 U.S. Public Health Service Guideline: Treating Tobacco Use and

Dependence; early draft released in October 2007.

(2) Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and

Dependence. Clinical Practice Guideline. Rockville, MD.

(3) Stead LF, Perera R, Bullen C,Mant D, Lancaster T. Nicotine replacement

therapy for smoking cessation. Cochrane Database of Systematic Reviews

2008, Issue 1. Art. No.: CD000146. DOI:

10.1002/14651858.CD000146.pub3.

(4) Centers for Disease Control and Prevention. Use of FDA-approved

pharmacologic treatments for tobacco dependence. Morbidity and

Mortality Weekly Report 2000; 49: 665-668.


'/>"/>
SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement by UHW President Sal Rosselli on SEIU Threat to Sue UHW Leaders
2. Pelosi Statement on Cover the Uninsured Week
3. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
4. Statement by H.E. Jakaya Mrisho Kikwete, President of the United Republic of Tanzania, and Chairman of the African Union, in Response to UN-SG Call to Action on Malaria
5. AHIP Statement on Senate Passage of the Genetic Information Nondiscrimination Act
6. SEIU RN Dian Palmer Calls on AFL-CIO Head John Sweeney to Review Video From Dearborn Protest, Retract Statement Accepting CNA Distortions
7. CNA/NNOC Statement on Restraining Order Against SEIU: Threats, Harassment and Stalking of RNs Remain Out of Bounds
8. Statement: Congress Should Include the Physician Self-Referral Provision in the Farm Bill for Patients and Communities
9. Statement From Larry Minnix, President & CEO, American Association of Homes and Services for the Aging (AAHSA) on the Senate Special Committee on Aging Hearing, Caring for Our Seniors: How Can We Support the Frontlines?
10. Statement by SEIU International President Andy Stern Regarding CNA Temporary Restraining Order
11. Statement of the American Diabetes Association Supporting Federal Courts Ruling on New York City Proposal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... , ... February 26, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Belmont, and Palo Alto, is proud to announce an important upgrade ... Area consumers look for home care close to home, and by having city-specific pages, ...
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today it ... at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, ... health analytics to improve Medicaid population health management. , ODH will also have an ...
(Date:2/24/2017)... Prior Lake MN (PRWEB) , ... February 24, ... ... the launch of its newly designed TaskMate Go. Core benefits and advantages built ... grain finish and a stylish, functional look and feel. Ability to gain the ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic ... Pittsburgh points to eight genes that may explain why susceptibility to one of the ... of a study published today in the journal npj Schizophrenia. , “There is ...
(Date:2/24/2017)... ... , ... With millions of Americans and people worldwide struggling ... are aware of our options and are empowered with strength and information throughout ... its newest edition of "Vision and Hearing" in USA Today, that will educate ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017  Today, exocad America and the Biodenta ... new path to produce 510(K) cleared, in-house milled, ... integrated into exocad DentalCAD software. In order to ... Manufacturing Processes (GMP,s) into their organization, sign up ... an audit process. Then, dental labs can use Biodenta,s ...
(Date:2/24/2017)... , Feb. 24, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the Cowen and Company ... Boston Marriott Copley Place on Tuesday, March 7, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
(Date:2/24/2017)... Research and Markets has announced the addition of the "Dry ... offering. ... Dry eye Drugs Price Analysis and Strategies - 2016, provides drug pricing ... answers the following questions: What are the ... they positioned in the Global Dry eye market? What ...
Breaking Medicine Technology: